Pu-Ad

Solid Malignancy

Samus Therapeutics, Inc.Early Phase 1Dormant

D

20/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 5/ 100
Competitive Position: 95/ 100

Competitive context

1412 Active assets in the Solid Malignancy cohort.

Asset / Sponsor	Phase	Rating
Nabiximols Jazz Pharmaceuticals	Phase 3	BBB
Inno-206 M.D. Anderson Cancer Center	Phase 2	BB
Vitamin B6 M.D. Anderson Cancer Center	Phase 4	BB
PROPOFOL Hong Kong Children's Hospital	Phase 4	BB
Rivoceranib Jiangsu HengRui Medicine Co., Ltd.	Phase 4	BB

View all 50 →

Same molecule, other indications

Pu-Ad is also rated in:

Alzheimer diseaseDormant

D

Indicative ·

30 / 100

amyotrophic lateral sclerosisDormant

D

Indicative ·

29 / 100

lymphomaDormant

D

Indicative ·

20 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.